MSTQX
Price
$13.97
Change
-$0.04 (-0.29%)
Updated
Sep 20 closing price
VFIAX
Price
$527.71
Change
-$1.02 (-0.19%)
Updated
Sep 20 closing price
Ad is loading...

MSTQX vs VFIAX

Header iconMSTQX vs VFIAX Comparison
Open Charts MSTQX vs VFIAXBanner chart's image
Morningstar US Equity
Price$13.97
Change-$0.04 (-0.29%)
VolumeN/A
CapitalizationN/A
Vanguard 500 Index Admiral
Price$527.71
Change-$1.02 (-0.19%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
MSTQX vs VFIAX Comparison Chart
Loading...
VS
MSTQX vs. VFIAX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MSTQX is a StrongBuy and VFIAX is a Buy.

FUNDAMENTALS
Fundamentals
VFIAX has more cash in the bank: 1.24T vs. MSTQX (1.74B). VFIAX pays higher dividends than MSTQX: VFIAX (1.32) vs MSTQX (0.85). MSTQX was incepted earlier than VFIAX: MSTQX (6 years) vs VFIAX (24 years). MSTQX is a more actively managed with annual turnover of: 53.00 vs. VFIAX (2.00). MSTQX has a lower initial minimum investment than VFIAX: MSTQX (0) vs VFIAX (3000). VFIAX annual gain was more profitable for investors over the last year : 31.72 vs. MSTQX (27.66). VFIAX return over 5 years is better than : 90.47 vs. MSTQX (36.42).
MSTQXVFIAXMSTQX / VFIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence6 years24 years-
Gain YTD18.02919.97190%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.74B1.24T0%
Annual Yield % from dividends0.851.3264%
Returns for 1 year27.6631.7287%
Returns for 3 years1.8030.996%
Returns for 5 years36.4290.4740%
Returns for 10 yearsN/A190.48-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BLBD54.491.17
+2.19%
Blue Bird Corp
MPLX44.200.07
+0.16%
Mplx LP
AIP7.45-0.08
-1.06%
Arteris
FFIN38.10-0.74
-1.91%
First Financial Bankshares
TPST1.35-0.06
-4.26%
Tempest Therapeutics